Phase II Study of crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors with the D842-related mutations or deletions, including the D842V Mutation in the PDGFRA Gene
The purpose of this study is to find out what effects, good or bad, the study drug – crenolanib (CP-868,596) – has on subjects with advanced Gastrointestinal Stromal Tumors (GIST) with the D842-related mutations or deletions, including the D842V mutation in the PDGFRA (Platelet Derived Growth Factor Receptor) gene.
* Subjects must be 18 years or older
* Subjects must have been diagnosed with GIST with a D842-related mutation or deletion on the PDGFRA gene
* Subjects must have received prior chemotherapy or radiation therapy
18 - 100
Healthy Volunteers Needed
Duration of Participation
Subjects will be given an oral drug twice a day and followed closely for side effects. Subjects will return for weekly clinic visits for the first month of treatment, then return for clinic visits every two weeks during the second month. Subjects will then return to clinic once every two months (for two visits), then once every three months until the end of their study participation.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
AROG Pharmaceuticals, LLC